ESC 365 - Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: Insights from the randomised controlled TRITON study

ESC Premium Access

Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: Insights from the randomised controlled TRITON study

Session: Deep Dive into Pulmonary Arterial Hypertension and Myocardial Disease

Topic: Pulmonary Hypertension

Speaker: Professor N. Galie (Bologna, IT)

Event: ESC Congress 2020

Congress Presentation

About the speaker

Professor Nazzareno Galie

Alma Mater Studiorum, University of Bologna, Bologna (Italy)

14 presentations

2 followers

2 more presentations in this session

Atrial strain in cardiacATTR amyloidosis from pathophysiology to prognosis: is it time to rethink our approach to disease?

Speaker: Doctor F. Bandera (Milan, IT)

High prevalence of familial and genetic disease in children with cardiomyopathies: Baseline paediatric data from the ESC EORP Cardiomyopathy and Myocarditis Registry

Speaker: Associate Professor J. Kaski (London, GB)

Access the full session

Deep Dive into Pulmonary Arterial Hypertension and Myocardial Disease

Speakers: Professor N. Galie, Doctor F. Bandera, Associate Professor J. Kaski

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

Related content

Open Access

Long-term outcomes in PAH: Optimised approach to achieve the best outcomes.

27 August 2021

ESC Premium Access

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Impact of COVID-19 pandemics upon pulmonary hypertension patients: insights from BNP-PL national database

27 August 2021

ESC 365 is supported by